Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Ionis Pharma up 5% premarket after marketing partner Biogen (BIIB) reported Q1 Spinraza sales of $47 mln, well above estimates (45.74)Spinraza is the first approved drug for Spinal Muscular Atrophy (SMA)</td> </tr></table>"